These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 21925231)

  • 41. Morin Attenuates Neurochemical Changes and Increased Oxidative/Nitrergic Stress in Brains of Mice Exposed to Ketamine: Prevention and Reversal of Schizophrenia-Like Symptoms.
    Ben-Azu B; Aderibigbe AO; Eneni AO; Ajayi AM; Umukoro S; Iwalewa EO
    Neurochem Res; 2018 Sep; 43(9):1745-1755. PubMed ID: 29956036
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structural investigation of heteroyohimbine alkaloid synthesis reveals active site elements that control stereoselectivity.
    Stavrinides A; Tatsis EC; Caputi L; Foureau E; Stevenson CE; Lawson DM; Courdavault V; O'Connor SE
    Nat Commun; 2016 Jul; 7():12116. PubMed ID: 27418042
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The putative antipsychotic alstonine reverses social interaction withdrawal in mice.
    de Moura Linck V; Herrmann AP; Goerck GC; Iwu MM; Okunji CO; Leal MB; Elisabetsky E
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1449-52. PubMed ID: 18539376
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anxiolytic properties of the antipsychotic alkaloid alstonine.
    Costa-Campos L; Dassoler SC; Rigo AP; Iwu M; Elisabetsky E
    Pharmacol Biochem Behav; 2004 Mar; 77(3):481-9. PubMed ID: 15006458
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of the putative antipsychotic alstonine on glutamate uptake in acute hippocampal slices.
    Herrmann AP; Lunardi P; Pilz LK; Tramontina AC; Linck VM; Okunji CO; Gonçalves CA; Elisabetsky E
    Neurochem Int; 2012 Dec; 61(7):1144-50. PubMed ID: 22940693
    [TBL] [Abstract][Full Text] [Related]  

  • 46. NU-1223, a simplified analog of alstonine, with 5-HT
    Rajagopal L; Mahjour S; Huang M; Ryan CA; Elzokaky A; Csakai AJ; Orr MJ; Scheidt K; Meltzer HY
    Behav Brain Res; 2023 Oct; 454():114614. PubMed ID: 37572758
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism.
    Neill JC; Barnes S; Cook S; Grayson B; Idris NF; McLean SL; Snigdha S; Rajagopal L; Harte MK
    Pharmacol Ther; 2010 Dec; 128(3):419-32. PubMed ID: 20705091
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
    Stahl SM; Shayegan DK
    J Clin Psychiatry; 2003; 64 Suppl 19():6-12. PubMed ID: 14728084
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment.
    Reynolds GP; Templeman LA; Zhang ZJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jul; 29(6):1021-8. PubMed ID: 15953671
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 5-HT2A/C receptors mediate the antipsychotic-like effects of alstonine.
    Linck VM; Bessa MM; Herrmann AP; Iwu MM; Okunji CO; Elisabetsky E
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Jan; 36(1):29-33. PubMed ID: 21925231
    [TBL] [Abstract][Full Text] [Related]  

  • 51.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 52.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.